## **IN THE CLAIMS**

This listing of claims will replace all prior versions and listings of claims in the application:

- 1. (Currently Amended) A medical kit for qualitative or quantitative determination of a drug in a biological fluid, said medical kit comprising:
- i) a first part coated with a drug conjugate wherein said first part consists of a stick; and
- ii) a second part which contains a labeled antidrug antibody being the specific binding partner of the drug conjugate and is adapted for receiving said biological fluid, wherein said labeled anti-drug antibody is labeled with gold material or latex particles,

wherein the qualitative or quantitative determination of the drug is achieved within at least 5 minutes but less than 30 minutes of the first part contacting the second part.

- 2. (Currently Amended) The medical kit according to claim 1, wherein said drug conjugate is a conjugate between a drug and either a protein, peptide, polyamine, ceramide, alkyl chain, or carbohydrate.
- 3. (Currently Amended) The medical kit according to claim 2, wherein said protein is selected from rabbit serum albumin, bovine serum albumin, ovalbumin, gamma globulin-and, or thyroglobulin.
- 4. (Previously Presented) The medical kit according to claim 1, wherein said latex particles are colored.

- 5. (Previously Presented) The medical kit according to claim 1, wherein said gold material is colloidal gold.
- 6. (Currently Amended) The medical kit according to claim 2, wherein said drug is selected from antihypertensive, antiviral, antimicrobial, antifungal, antiinflammatory, andor psychopharmaceutical agents, said psychopharmaceutical agents consisting of including corticosteroids, mono- to oligosaccharides, vitamins, provitamins or , and hormones.
- 7. (Previously Presented) The medical kit according to claim 6, wherein said drug has a molar weight in the range of from 50 to 6000 g/mol, preferably from 100 to 1000 g/mol.
- 8. (Currently Amended) The medical kit according to claim 7, wherein said drug is selected from lisinopril, amilodipine, captopril, enalapril, enalaprilat, ketotifen, sildenafil, or fluoxetine.
- 9. (Previously Presented) The medical kit according to claim 1, wherein said second part is a container which consists of a solution of said labeled anti-drug antibody or has its interior at least partially coated with said labeled anti-drug antibody.
  - 10. (Canceled)
  - 11. (Canceled)
- 12. (Previously Presented) The medical kit according to claim 10, wherein said first part has a surface of a material selected from polystyrene, polypropylene, or nitrocellulose material.

- 13. (Canceled)
- 14. (Previously Presented) The medical kit according to claim 9, wherein said container is tube-shaped.
- 15. (Currently Amended) The medical kit according to claim 1, wherein said biological fluid is blood, serum, or urine.
- 16. (Currently Amended) A method utilizing the medical kit according to claim 1 for the qualitative or quantitative determination of a drug in a biological fluid comprising the steps of:
  - (i) adding the biological fluid to said second part;
- (ii) bringing said first part into contact with the biological fluid in said second part for the qualitative and quantitative determination of the drug in the fluid;
- (iii) removing said first part from said second part after a predetermined period of time; and
- (iv) determining the color change of said first part indicating the qualitative or quantitative determination of the drug in the biological fluid, wherein the determination of the drug is achieved within at least 5 minutes but less than 30 minutes from the beginning of step (ii).

wherein the qualitative or quantitative determination of the drug is achieved within at least 5 minutes but less than 30 minutes of the first part contacting the second part.

## 17. (Canceled)

- 18. (Canceled)
- 19. (Currently Amended) The method according to claim 16, wherein said first part is subsequently developed in order to bring about a potential color change indicating the level qualitative or quantitative determination of said drug in said biological fluid.
- 20. (Previously Presented) The method according to claim 16, wherein the method is performed at ambient temperature.
- 21. (Currently Amended) The method according to claim 16, wherein said biological fluid is blood, serum, urine, or saliva.
- 22. (Currently Amended) A medical kit for qualitative or quantitative determination of lisinopril in a biological fluid, said medical kit comprising:
- i) a first part coated with a drug conjugate, wherein the drug conjugate is lisinoprilrabbit serum albumin; and
- ii) a second part, which is adapted for receiving the biological fluid, and which contains an anti-lisinopril antibody labeled with gold material, wherein the anti-lisinopril antibody is the specific binding partner of lisinopril-rabbit serum albumin, and wherein qualitative or quantitative determination of the drug is achieved within at least 5 minutes but less than 30 minutes after the first part comes in contact with the second part containing said biological fluid.

wherein the qualitative or quantitative determination of lisinopril is achieved within at least 5 minutes but less than 30 minutes of the first part contacting the second part.

- 23. (Currently Amended) A method utilizing the medical kit according to claim 22 for the qualitative or quantitative determination of lisinopril in a biological fluid comprising the steps of:
  - (i) adding the biological fluid to said second part;
- (ii) bringing said first part into contact with the biological fluid in said second part for the qualitative and quantitative determination of the lisinopril in the fluid;
- (iii) removing said first part from said second part within at least 5 minutes but less than 30 minutes after a predetermined period of time; and
- (iv) determining the color change of said first part indicating the qualitative or quantitative determination of lisinopril in the biological fluid[[.]],

wherein the qualitative or quantitative determination of lisinopril is achieved within at least 5 minutes but less than 30 minutes of the first part contacting the second part.